Exosome-targeted DNA vaccine
US12319727B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2023 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Aug 11, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/43
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.